Literature DB >> 8491266

Injections of calmidazolium chloride into the ipsilateral medial vestibular nucleus or fourth ventricle reduce spontaneous ocular nystagmus following unilateral labyrinthectomy in guinea pigs.

A J Sansom1, C L Darlington, P F Smith, D P Gilchrist, C J Keenan, R Kenyon.   

Abstract

The effects of three injections (0.5-4.5 h post-operation) of 1-[bis-(p-chlorophenyl)methyl]-3-[2,4-dichloro-beta-(2,4- dichlorobenzyloxy)phenethyl]-imidazolium chloride (calmidazolium chloride, R24571), into the ipsilateral medial vestibular nucleus or fourth ventricle, on vestibular compensation for unilateral labyrinthectomy was studied in guinea pigs. R24571, a calmodulin antagonist and inhibitor of several Ca(2+)-dependent enzymes, caused a significant reduction in the average frequency of spontaneous ocular nystagmus (spontaneous nystagmus) during the first 53 h following unilateral labyrinthectomy (n = 5), compared with vehicle-injected animals (n = 5). Although a statistical analysis was not performed on the yaw head tilt and roll head tilt data because of the large variability between animals over the 53-h period of compensation, most R24571-treated animals had less yaw head tilt (4/4 animals) and roll head tilt (4/5 animals) at 9-11 h post-labyrinthectomy than the average values for the vehicle groups at that time. The decrease in the frequency of spontaneous nystagmus following R24571 treatment was not associated with general ataxia or sedation. These results are consistent with recent biochemical studies in suggesting that intracellular pathways associated with Ca2+ may be involved in the neuronal mechanisms of vestibular compensation following unilateral labyrinthectomy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491266     DOI: 10.1007/BF00228394

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  29 in total

1.  Identification of a B-50-like protein in frog brain synaptosomes.

Authors:  U Janssen; C Richter-Landsberg; A B Oestreicher; P N De Graaf; W H Gispen; H Flohr
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

Review 2.  Mechanisms of recovery following unilateral labyrinthectomy: a review.

Authors:  P F Smith; I S Curthoys
Journal:  Brain Res Brain Res Rev       Date:  1989 Apr-Jun

3.  Pre-treatment with a Ca2+ channel antagonist facilitates vestibular compensation.

Authors:  C L Darlington; P F Smith
Journal:  Neuroreport       Date:  1992-02       Impact factor: 1.837

Review 4.  Neuronal phosphoproteins. Mediators of signal transduction.

Authors:  P Greengard
Journal:  Mol Neurobiol       Date:  1987 Spring-Summer       Impact factor: 5.590

5.  Intraventricular injection of an N-methyl-D-aspartate antagonist disrupts vestibular compensation.

Authors:  A J Sansom; C L Darlington; P F Smith
Journal:  Neuropharmacology       Date:  1990-01       Impact factor: 5.250

6.  Reflex control of acute postural asymmetry and compensatory symmetry after a unilateral vestibular lesion.

Authors:  D W Jensen
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

7.  Calcium antagonist effects on low-threshold (T-type) calcium current in rat isolated hippocampal CA1 pyramidal neurons.

Authors:  K Takahashi; N Akaike
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

8.  Pretreatment with MK-801 reduces spontaneous nystagmus following unilateral labyrinthectomy.

Authors:  A J Sansom; C L Darlington; P F Smith
Journal:  Eur J Pharmacol       Date:  1992-09-22       Impact factor: 4.432

9.  Effects of flunarizine on ocular motor and postural compensation following peripheral vestibular deafferentation in the guinea pig.

Authors:  D P Gilchrist; C L Darlington; P F Smith
Journal:  Pharmacol Biochem Behav       Date:  1993-01       Impact factor: 3.533

10.  The effects of N-methyl-D-aspartate antagonists on the development of vestibular compensation in the guinea pig.

Authors:  C L Darlington; P F Smith
Journal:  Eur J Pharmacol       Date:  1989-12-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.